文献速递脑血管病

急性再灌注治疗的辅助抗栓药物:当前证据与未来方向

Adjunctive Antithrombotic Medications to Acute Reperfusion Therapy: Current Evidence and Future Directions.
PubMed 文献 · Stroke · 2025-07-28

溶栓和机械取栓是急性缺血性卒中的标准治疗,优化再灌注是改善预后的关键。抗栓药物在卒中二级预防中的作用已明确,但作为急性期辅助再灌注治疗的作用仍在研究中。本文讨论辅助抗栓药物联合再灌注治疗的理论依据,回顾关键试验,并展望未来方向。

要点

  • 溶栓和取栓是急性缺血性卒中标准治疗,优化再灌注是改善预后的关键。
  • 抗栓药物在二级预防中作用明确,但急性期辅助再灌注的作用仍在研究。
  • 本文回顾辅助抗栓药物联合再灌注的关键试验并讨论未来方向。

核心结论

  • 抗栓药物作为急性再灌注治疗的辅助手段仍处于研究阶段,其疗效需进一步试验验证。

研究设计与样本

  • 本文为综述,讨论辅助抗栓药物联合溶栓或取栓的理论依据并回顾相关关键试验。

主要发现

  • 溶栓和机械取栓是急性缺血性卒中标准治疗,优化再灌注是改善患者预后的关键下一步。
  • 抗栓药物在卒中二级预防中的作用已明确,但急性期辅助再灌注的作用仍在研究中。

临床怎么用

  • 本文讨论辅助抗栓药物在当前再灌注策略中的未来及院内抗栓药物的最佳使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Thrombolytics and mechanical thrombectomy are standard of care therapies for the treatment of acute ischemic stroke. Optimizing reperfusion beyond these 2 interventions is a critical next step to improving patient outcomes. The utility of antithrombotic medications is well-established for secondary stroke prevention, but their role as adjunctive therapies to achieve or optimize reperfusion in the acute setting remains investigational. This article discusses the rationale for the use of adjunctive antithrombotic medications in combination with reperfusion therapies and reviews key trials exploring their use. We will use the term adjunctive to refer to any antithrombotic intervention that is added acutely to the standard of care of thrombolysis or thrombectomy to improve patient outcomes. A brief discussion on the future of adjunctive therapies for current reperfusion strategies and the best use of antithrombotic medications in the hospital setting are additionally presented.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Menzies LE, Aziz YN, Adeoye O, et al. Adjunctive Antithrombotic Medications to Acute Reperfusion Therapy: Current Evidence and Future Directions. Stroke. 2025. PMID: 40720571. doi:10.1161/STROKEAHA.125.051818

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。